$CGTX
Cognition Therapeutics, Inc. Common Stock
XNAS
Why is CGTX up today? It is at $1.14 (+7.08%), and our scanner flagged it 2 times on unusual volume this month. See the catalyst behind the move, real-time alerts the moment CGTX spikes, and full due diligence on CGTX — key stats, earnings, dilution and insider activity. Free.
Get free $CGTX alerts the moment volume spikes
Our scanner flagged $CGTX 2 times in the last 30 days. Create a free account to track $CGTX, build a watchlist, and get instant unusual-volume alerts — plus 5 free premium days, no card needed.
No card · 5 premium days · join 800+ traders
Key Stats
- Price
- $1.14
- Change today
- +7.08%
- Previous close
- $1.06
- 52-week range
- $0.550 – $3.83
- Market cap
- $95M
- Institutional own.
- 28.80%
- Total held
- 40.3%
- Tradeable float
- 53.4M 60% of shares · after 12% insiders + 29% institutions
- Short interest
- 9.7M ▲ +37% vs prior · as of 2026-07-15
- Short % of float
- 18.1%
- Days to cover
- 4.8d
- Avg daily volume
- 2.3M
- Exchange
- XNAS
- 5m
- 1.9x
- 15m
- 3.0x
- 1h
- 2.3x
- 1D
- 0.4x
Get free CGTX + market alerts in your inbox
The top plays and unusual-volume catches our scanner flags, emailed to you. No account needed.
No spam. Unsubscribe anytime. Not investment advice.
Why is $CGTX up today?
Here is the latest on CGTX from our scanner (live price and day move above). A move this size is almost always tied to a specific catalyst. Most of the time that is an earnings report, a guidance update, or a company announcement. If none is shown above, the release may not be in our news feed yet. It will show up here as soon as it is.
Likely catalystCognition Therapeutics Aligns on Key AspectsReported and delusions by 89%. In July, the Company will present additional analyses from the Phase 2 study showing zervimesine's impactReported promise in Phase 2 clinical trials in DLB and mild-to-moderate Alzheimer's disease. Backed by nearly $200 million in National InstitutesReported disease characterized by neuropsychiatric, cognitive and motor deficits. Up to 80% of people living with DLB experience psychosis, which, from the latest SEC filing. Read it →Analyst data via Nasdaq. Not investment advice.
Insiders
Insiders buying3 open-market buys5 buys, 0 sells last 3 months (14/12 over 12 months)Show 12 recent transactionsMinimize 12 recent transactions
| Insider | Action | Shares | % of position | Owns after | Value | Date |
|---|---|---|---|---|---|---|
Fletcher Aaron G.L. Director | Acquired (grant/award) | +25K 0.03% of company | added 44% | 81K | n/a | Jun 17, 26 |
Richstone Ellen B Director | Acquired (grant/award) | +25K 0.03% of company | added 43% | 84K | n/a | Jun 17, 26 |
Wallace Peggy Director | Acquired (grant/award) | +25K 0.03% of company | added 29% | 111K | n/a | Jun 17, 26 |
Monia Brett P Director | Acquired (grant/award) | +25K 0.03% of company | added 52% | 74K | n/a | Jun 17, 26 |
Khattar Jack A. Director | Acquired (grant/award) | +25K 0.03% of company | added 52% | 74K | n/a | Jun 17, 26 |
Doyle John Brendan Officer | Sold (automatic/other) | -9K | sold 1.4% | 619K | $11K at $1.28 | May 1, 26 |
Caggiano Anthony Officer | Bought (open market) | +10K 0.01% of company | added 1.2% | 875K | $11K at $1.11 | Apr 16, 26 |
Ricciardi Lisa Officer | Bought (open market) | +9K 0.01% of company | added 0.5% | 1.72M | $10K at $1.10 | Apr 16, 26 |
Doyle John Brendan Officer | Bought (open market) | +10K 0.01% of company | added 1.6% | 628K | $11K at $1.13 | Apr 16, 26 |
Caggiano Anthony Officer | Sold (automatic/other) | -5K | sold 0.5% | 865K | $5K at $1.12 | Feb 15, 26 |
Doyle John Brendan Officer | Sold (automatic/other) | -2K | sold 0.3% | 618K | $2K at $1.12 | Feb 15, 26 |
Ricciardi Lisa Officer | Sold (automatic/other) | -6K | sold 0.3% | 1.71M | $7K at $1.12 | Feb 15, 26 |
Recent Form-4 filings via Nasdaq. Open-market buys are the signal worth watching. Grants and automatic (10b5-1) sells are routine. “% of position” is the share of that insider’s own holding the trade moved. Not investment advice.
Dilution watch
Active shelfActive shelf on file — the company can issue new shares on demand (valid ~3 years). If $CGTX runs, these filings show who may be positioned to sell new or newly-registered shares into the move.
Sourced from SEC EDGAR filings (last 9 months); terms read straight from the filing text where available. Ongoing = an at-the-market (ATM) program still selling over time or a live shelf, so it can keep diluting; Completed = a one-time priced sale that already finished. A shelf (S-3) stays effective ~3 years. Form type signals dilution capacity, not an exact share count, and we can't confirm how much of a shelf or ATM remains unused. Not investment advice.
$CGTX Sentiment
BullishBlend of news sentiment, today’s move, and community votes. Not investment advice.
$CGTX Activity
News, unusual-volume alerts, AI-trader trades and community chatter — the whole story, newest first.
CGTX stock FAQ
Why is $CGTX up today?
Here is the latest on CGTX from our scanner (live price and day move above). A move this size is almost always tied to a specific catalyst. Most of the time that is an earnings report, a guidance update, or a company announcement. If none is shown above, the release may not be in our news feed yet. It will show up here as soon as it is.
What is the CGTX stock price today?
CGTX last traded at $1.14, up 7.08% on the day. The price and chart above update live during market hours (4 AM to 8 PM ET).
Where can I see live CGTX alerts?
The CGTX Live Alerts panel on this page streams real-time unusual volume (RVOL), momentum, halt and 200-EMA alerts from our scanner the moment they fire. Our scanner has flagged CGTX 2 times in the last 30 days.
What exchange is CGTX on?
CGTX (Cognition Therapeutics, Inc. Common Stock) trades on XNAS, with a market cap of about $95M.
Is CGTX good for day trading?
That depends on your strategy and risk. Day traders look for volume, volatility and a clear trend. Use the live chart, RVOL alerts and 200-EMA context on this page to judge CGTX for yourself. This is not investment advice.
Live data from TheDesperateTrader scanner. Not investment advice.